Calithera Biosciences Stock Forecast, Price & News

-0.05 (-2.38 %)
(As of 09/16/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.13 million shs
Average Volume1.13 million shs
Market Capitalization$151.93 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CALA News and Ratings via Email

Sign-up to receive the latest news and ratings for Calithera Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Calithera Biosciences logo

About Calithera Biosciences

Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor. The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.23 out of 5 stars

Medical Sector

315th out of 1,352 stocks

Pharmaceutical Preparations Industry

149th out of 665 stocks

Analyst Opinion: 3.3Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Calithera Biosciences (NASDAQ:CALA) Frequently Asked Questions

Is Calithera Biosciences a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Calithera Biosciences in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Calithera Biosciences stock.
View analyst ratings for Calithera Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Calithera Biosciences?

Wall Street analysts have given Calithera Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Calithera Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Calithera Biosciences?

Calithera Biosciences saw a increase in short interest in the month of August. As of August 13th, there was short interest totaling 2,660,000 shares, an increase of 35.0% from the July 29th total of 1,970,000 shares. Based on an average trading volume of 826,800 shares, the days-to-cover ratio is currently 3.2 days. Approximately 3.9% of the company's stock are sold short.
View Calithera Biosciences' Short Interest

When is Calithera Biosciences' next earnings date?

Calithera Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Calithera Biosciences

How were Calithera Biosciences' earnings last quarter?

Calithera Biosciences, Inc. (NASDAQ:CALA) announced its quarterly earnings data on Thursday, August, 5th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.24) by $0.05. The biotechnology company earned $3 million during the quarter.
View Calithera Biosciences' earnings history

How has Calithera Biosciences' stock been impacted by Coronavirus (COVID-19)?

Calithera Biosciences' stock was trading at $5.23 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CALA stock has decreased by 60.8% and is now trading at $2.05.
View which stocks have been most impacted by COVID-19

What price target have analysts set for CALA?

2 brokers have issued 12 month price targets for Calithera Biosciences' shares. Their forecasts range from $2.00 to $5.00. On average, they expect Calithera Biosciences' stock price to reach $3.67 in the next twelve months. This suggests a possible upside of 78.9% from the stock's current price.
View analysts' price targets for Calithera Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Calithera Biosciences' key executives?

Calithera Biosciences' management team includes the following people:
  • Susan M. Molineaux, President, Chief Executive Officer & Director
  • Stephanie Wong, Secretary, Chief Financial & Accounting Officer
  • Susan B Demo, Vice President-Medical Affairs
  • Francesco Parlati, Senior Vice President-Research
  • Keith Orford, Chief Medical Officer

Who are some of Calithera Biosciences' key competitors?

What other stocks do shareholders of Calithera Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Calithera Biosciences investors own include Puma Biotechnology (PBYI), Incyte (INCY), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), Celadon Group (CGI), Dynavax Technologies (DVAX), Rigel Pharmaceuticals (RIGL), First Solar (FSLR), Plug Power (PLUG) and Sorrento Therapeutics (SRNE).

What is Calithera Biosciences' stock symbol?

Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."

Who are Calithera Biosciences' major shareholders?

Calithera Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Primecap Management Co. CA (13.97%), BVF Inc. IL (9.85%), Vanguard Group Inc. (3.96%), BlackRock Inc. (3.77%), Dimensional Fund Advisors LP (1.85%) and Millennium Management LLC (1.64%). Company insiders that own Calithera Biosciences stock include Bvf Partners L P/Il, Keith Orford, Stephanie Wong and Value Fund L P Biotechnology.
View institutional ownership trends for Calithera Biosciences

Which institutional investors are selling Calithera Biosciences stock?

CALA stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Vanguard Group Inc., Northern Trust Corp, Geode Capital Management LLC, Bank of New York Mellon Corp, Susquehanna International Group LLP, and Charles Schwab Investment Management Inc..
View insider buying and selling activity for Calithera Biosciences
or view top insider-selling stocks.

Which institutional investors are buying Calithera Biosciences stock?

CALA stock was acquired by a variety of institutional investors in the last quarter, including BVF Inc. IL, Morgan Stanley, Morgan Stanley, Millennium Management LLC, Ergoteles LLC, Bridgeway Capital Management LLC, Renaissance Technologies LLC, and Walleye Capital LLC. Company insiders that have bought Calithera Biosciences stock in the last two years include Bvf Partners L P/Il, and Value Fund L P Biotechnology.
View insider buying and selling activity for Calithera Biosciences
or or view top insider-buying stocks.

How do I buy shares of Calithera Biosciences?

Shares of CALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Calithera Biosciences' stock price today?

One share of CALA stock can currently be purchased for approximately $2.05.

How much money does Calithera Biosciences make?

Calithera Biosciences has a market capitalization of $151.93 million and generates $22.25 million in revenue each year. The biotechnology company earns $-90,140,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis.

How many employees does Calithera Biosciences have?

Calithera Biosciences employs 93 workers across the globe.

What is Calithera Biosciences' official website?

The official website for Calithera Biosciences is

Where are Calithera Biosciences' headquarters?

Calithera Biosciences is headquartered at 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Calithera Biosciences?

Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at (650) 870-1000 or via email at [email protected]

This page was last updated on 9/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.